NASDAQ:LOXO Loxo Oncology (LOXO) Stock Price, News & Analysis → 8,788% Return Predicted For THIS Crypto (already up 40% in 6 months) (From Paradigm Press) (Ad) Free LOXO Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$234.66▼$234.6650-Day Range N/A52-Week Range$101.70▼$234.93Volume400 shsAverage Volume565,561 shsMarket Capitalization$7.18 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Loxo Oncology alerts: Email Address Ad The Bull ReportThe AI Bottleneck No One is Talking AboutRenewable energy is growing at an impressive speed - but not fast enough. This could be one of the greatest periods for the nuclear industry ever.Click here to see who's preparing to meet these needs About Loxo Oncology Stock (NASDAQ:LOXO)Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. The company's preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains. It has a drug discovery collaboration agreement with Array BioPharma, Inc. to obtain various rights to TRK inhibitor program and oncology targets; strategic partnership with Illumina, Inc. to develop and commercialize a multi-gene panel for broad tumor profiling; and research collaboration agreement with Veracyte, Inc. to develop medicines for patients with genetically defined cancers. Loxo Oncology, Inc. was founded in 2013 and is headquartered in Stamford, Connecticut.Read More Ad Colonial MetalsCentral Bank Gold Heist In ProgressWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide. LOXO Stock News HeadlinesMarch 11, 2024 | finance.yahoo.comMOMA Therapeutics Appoints Jullian G. Jones, Ph.D., J.D., MBA, as Chief Business OfficerFebruary 26, 2024 | benzinga.comDavid M Mott's Net WorthMarch 19, 2024 | Prosper Trading Academy (Ad)Did you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:February 8, 2024 | bizjournals.comFoghorn gets $300M plus investment from Lilly under cancer drug partnershipJanuary 18, 2024 | msn.comEli Lilly’s Jaypirca to lead BTK inhibitor market for leukemiaJanuary 10, 2024 | msn.comIron Condor Alert: LLY Stock Could Net 40% In 4 WeeksJanuary 8, 2024 | finance.yahoo.cominsitro Hires Chief Medical Officer to Advance Therapeutic Programs Toward the ClinicJanuary 8, 2024 | markets.businessinsider.comFoghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024March 19, 2024 | Prosper Trading Academy (Ad)Did you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:December 5, 2023 | msn.comEli Lilly surprised as POINT Biopharma acquisition remains incompleteDecember 4, 2023 | finance.yahoo.comLilly cancer drug cleared by FDA for expanded leukemia, lymphoma useNovember 4, 2023 | finance.yahoo.comEli Lilly and Company (NYSE:LLY) Q3 2023 Earnings Call TranscriptNovember 2, 2023 | finanznachrichten.deFoghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate UpdateNovember 2, 2023 | ca.investing.comCiti continue to see upside to Eli Lilly & Co.'s 'already rich' valuationNovember 2, 2023 | finance.yahoo.comFoghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate UpdateOctober 4, 2023 | msn.comLilly agrees to buy POINT Biopharma for $1.4bnOctober 4, 2023 | msn.comEli Lilly to pay $1.4-billion for cancer-drug maker Point BiopharmaOctober 3, 2023 | thestreet.comPoint Biopharma stock soars on $1.4B takeover bid from Eli LillyOctober 3, 2023 | msn.comPOINT Biopharma (NASDAQ: PNT) Soars After Eli Lilly’s $1.4 Billion AcquisitionOctober 3, 2023 | msn.comEli Lilly to Pay $1.4 Billion for Cancer-Drug Maker Point BiopharmaOctober 3, 2023 | msn.comEli Lilly Acquiring Cancer Therapy Developer For $1.4 Billion—A Nearly 90% PremiumSeptember 26, 2023 | finanznachrichten.deBiocartis Group NV: Biocartis appoints new Medical Advisory Board (MAB) of renowned practice leadersAugust 28, 2023 | finance.yahoo.comPress Release Biocartis Group NV: Biocartis appoints new Medical Advisory Board (MAB) of renowned practice leadersAugust 25, 2023 | benzinga.comPropulsion of Medullary Thyroid Cancer Clinical Trial Pipeline as Novel and Extensive 15+ Therapies Likely to Enter in the Domain | DelveInsightAugust 16, 2023 | msn.comNext-generation study launched via LSUHS partnership to aid rural cancer patientsAugust 10, 2023 | finanznachrichten.deBiocartis Group NV: Biocartis Partners with Lilly to Explore Biomarker Testing for NSCLC Patients using the Idylla PlatformAugust 10, 2023 | finance.yahoo.comPress Release Biocartis Group NV: Biocartis Partners with Lilly to Explore Biomarker Testing for NSCLC Patients using the Idylla™ PlatformSee More Headlines Receive LOXO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Loxo Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/09/2018Today3/18/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:LOXO CUSIPN/A CIK1581720 Webwww.loxooncology.com Phone203-653-3880FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($5.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-148,870,000.00 Net Margins-43.49% Pretax MarginN/A Return on Equity-16.42% Return on Assets-8.66% Debt Debt-to-Equity RatioN/A Current Ratio3.62 Quick Ratio3.62 Sales & Book Value Annual Sales$21.30 million Price / Sales337.23 Cash FlowN/A Price / Cash FlowN/A Book Value$12.63 per share Price / Book18.58Miscellaneous Outstanding Shares30,610,000Free FloatN/AMarket Cap$7.18 billion OptionableOptionable Beta2.51 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Joshua H. Bilenker (Age 47)Founder, Pres, CEO & Director Ms. Jennifer Burstein M.B.A. CPA (Age 47)Sr. VP of Fin. Mr. Jacob S. Van Naarden (Age 34)Chief Operating Officer Ms. Jennifer L. KronickVP of HRDr. Nisha Nanda (Age 44)Chief Devel. Officer Key CompetitorsApellis PharmaceuticalsNASDAQ:APLSJazz PharmaceuticalsNASDAQ:JAZZCerevel TherapeuticsNASDAQ:CERECytokineticsNASDAQ:CYTKElanco Animal HealthNYSE:ELANView All Competitors LOXO Stock Analysis - Frequently Asked Questions How were Loxo Oncology's earnings last quarter? Loxo Oncology Inc (NASDAQ:LOXO) released its earnings results on Thursday, August, 9th. The biopharmaceutical company reported ($0.39) EPS for the quarter, topping analysts' consensus estimates of ($0.54) by $0.15. The biopharmaceutical company had revenue of $42.60 million for the quarter, compared to analysts' expectations of $32.36 million. Loxo Oncology had a negative net margin of 43.49% and a negative trailing twelve-month return on equity of 16.42%. During the same quarter last year, the business earned ($0.94) EPS. What other stocks do shareholders of Loxo Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Loxo Oncology investors own include Alibaba Group (BABA), GW Pharmaceuticals (GWPH), NVIDIA (NVDA), Netflix (NFLX), AbbVie (ABBV), Micron Technology (MU), Advanced Micro Devices (AMD) and Johnson & Johnson (JNJ). This page (NASDAQ:LOXO) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressAltcoin FRENZY Alert…Crypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportThe world’s greatest investmentPorter & CompanyMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Loxo Oncology Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.